Ireland· IE-PA-EU/1/16/1087/002
Coagadex 500 IU powder and solvent for solution for injection
A coagulation factor x product containing human coagulation factor x, registered in Ireland by Kedrion S.p.A.. The same ATC class is registered in 9 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Coagulation factor x is registered in 9 of 19 countries.
Countries holding a registration under ATC B02BD13 (coagulation factor x), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 6 of them publish a price we can compare per daily dose
Coagulation factor x · ATC B02BD13
9 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
The record
At a glance
HPRA (Ireland)- Active substance
- Human coagulation factor x
- Manufacturer
- Kedrion S.p.A.
- Country
- Ireland (IE)
- ATC code
- B02BD13
- ATC class
- Coagulation factor X
- Defined daily dose
- 1.75 TSD, E
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberEU/1/16/1087/002
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
8 interactions on record for coagulation factor x.
Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Coagulation factor x · interactions on record
8 records
- 2 severe
- 6 moderate
Most severe, free to view
- CarfilzomibL01XG02severe
- CarfilzomibL01XX45severe
- RivaroxabanB01AF01moderate
- ApixabanB01AF02moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Coagulation factor x in 10 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandCoagadexKedrion S.p.A
- BelgiumCoagadex 250 IUKedrion
- United KingdomCoagadex 250unit powder and solvent for solution for injection vialsBio Products Laboratory Ltd
- SpainCOAGADEX 250 UI POLVO Y DISOLVENTE PARA SOLUCION INYECTABLEKedrion S.P.A.
- PolandCoagadexBPL Bioproducts Laboratory GmbH
- CzechiaCOAGADEXKEDRION S.P.A., BARGA (LU)
- SwedenCoagadex 250 IE Pulver och vätska till injektionsvätska, lösningKedrion S.p.A
- IcelandCoagadexKedrion S.p.A.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/8c1f37e5-9e38-4f59-9c5e-190bd2062849 GET /v1/drugs/8c1f37e5-9e38-4f59-9c5e-190bd2062849?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Powder and solvent for solution for injection",
"routes": [
"Intravenous use"
],
"source": "hpra",
"atc_all": [
"B02BD",
"B02BD13"
],
"strength": null,
"pa_number": "EU/1/16/1087/002",
"substances": [
"Human coagulation factor x"
],
"legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
"market_info": "Unknown",
"authorised_at": "16/03/2016",
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about coagulation factor x.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.